BioVie Inc., a Nevada-based biopharmaceutical company, has filed an amendment to its previous Current Report on Form 8-K with the Securities and Exchange Commission. The amendment, dated August 1, 2024, pertains to the company's reverse stock split that was initially reported on July 31, 2024. The recent filing includes the Certificate of Termination and the Certificate of Amendment related to the one-for-ten reverse stock split of BioVie's common stock. The Certificate of Amendment, filed on August 2, 2024, corrected a defect in the original filing, while the Certificate of Termination, filed on August 5, 2024, nullified the initial Certificate of Change. Despite these administrative adjustments, there were no substantive changes to the terms or the timing of the reverse stock split as previously disclosed. The documents related to these filings, including the Certificate of Termination and the Certificate of Amendment, have been provided as exhibits under Item 9.01 in the amended report.

BioVie Inc., a Nevada-based biopharmaceutical company, has filed an amendment to its previous Current Report on Form 8-K with the Securities and Exchange Commission. The amendment, dated August 1, 2024, pertains to the company's reverse stock split that was initially reported on July 31, 2024. The recent filing includes the Certificate of Termination and the Certificate of Amendment related to the one-for-ten reverse stock split of BioVie's common stock. The Certificate of Amendment, filed on August 2, 2024, corrected a defect in the original filing, while the Certificate of Termination, filed on August 5, 2024, nullified the initial Certificate of Change. Despite these administrative adjustments, there were no substantive changes to the terms or the timing of the reverse stock split as previously disclosed. The documents related to these filings, including the Certificate of Termination and the Certificate of Amendment, have been provided as exhibits under Item 9.01 in the amended report.